For research and educational purposes only. Not medical advice.
OPK-88004 Reference
Educational, not medical advice reference for OPK-88004: SARM, Hormonal; regulatory status, evidence posture, source review, and schedule notes. Also known a…
Reference summary
A randomized trial in prostate-cancer survivors evaluated sexual symptoms, body composition, and physical function. It did not establish broad clinical benefit or an approved indication.
- Categories
- SARM, Hormonal
- Aliases
- OPK88004, 4-chloro-17α-methyl-andro-4-ene-3β,17β-diol, Steroidal SARM
- Evidence posture
- human — Human trial context was prostate-cancer survivorship, not bodybuilding. Published results do not validate community sexual-function, testosterone-replacement, or performance claims. WADA-prohibited; no FDA approval.
- Regulatory status
- No FDA-approved OPK-88004 drug label. FDA consumer warnings against SARMs sold in bodybuilding products apply to the class. WADA prohibits SARMs under category S1.2 anabolic agents at all times.
- Content review status
- research reference